Charles Butt has provided funding for a permanent scholarship fund. Photo courtesy of Texas State History Museum Foundation

The leader of the Lone Star State’s beloved H-E-B has bestowed a monumental gift upon a historic Houston-area university.

On November 17, Prairie View A&M University announced that H-E-B chairman Charles Butt — one of America’s favorite CEOs and member of one of Texas’ richest families — has donated $5 million to create Founders Scholarships for incoming PVAMU students.

“The $5 million gift will provide a permanent endowment to support students today and in the coming years,” a release notes. “Initially generating approximately $200,000 a year for scholarships, the fund will grow significantly in coming years, making even more available to support students.”

The scholarships will be available to students from public high schools in Texas graduating in the top quartile of their class, the release says. They must be incoming first-year students, enrolled in a full-time course load, and as scholarship recipients, they will benefit from “enrichment opportunities unique to their [Founders Scholarships] cohort.”

Scholarship disbursements will begin in fall 2022, a spokesperson confirms; the number of initial scholarships available has not been revealed.

“Charles Butt has been amazingly generous to our university. He has shown time and time again that he genuinely cares about the opportunities afforded to students at PV. We are indebted to him for his grace and his humanity,” says Ruth Simmons, president of PVAMU, in the release.

Prairie View A&M University is the second-oldest public institution of higher learning in the state and is one of Texas’ historically Black universities. It is located approximately 50 miles northwest of Houston and has a current enrollment of more than 8,000 undergraduate and graduate students.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.